NASDAQ$ADAPY
Adaptimmune Therapeutics Plc · Q2 2023 earnings
Q2 2023 earnings · · Investor relations
Briefing
Reported financial results and business updates for Q2 2023.
Adaptimmune reported revenue of $5.1 million and a net loss of $21.4 million for the second quarter ended June 30, 2023. The company completed a strategic combination with TCR2, adding pipeline, technologies, approximately 40 people and $84.6 million in Total Liquidity at closing. They also anticipate completing the afami-cel BLA submission in Q4 2023 and have a cash runway into early 2026.
- Substantial progress on the afami-cel BLA with FDA agreement, submission targeted for Q4 2023.
- Transition of lete-cel from GSK with pivotal trial data expected in late 2023.
- Initiated Phase 2 SURPASS-3 trial in ovarian cancer, potentially registrational and supported by RMAT designation.
- Completed strategic combination with TCR2, adding pipeline, technologies, approximately 40 people and $84.6m in Total Liquidity.
Headline financials
Revenue & EPS history
Adaptimmune · Revenue · Quarterly
$5.13M
Revenue by segment
Adaptimmune · $1.42M total across 1 segment · Q4 2021
- Development revenue$1.42M—100.0%
Forward guidance
The Company believes that its existing cash, cash equivalents and marketable securities, together with the additional payments under the Strategic Collaboration and License Agreement with Genentech and payments under the Termination and Transfer Agreement with GSK, will fund the Company’s current operations into early 2026
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q2 2023
-3.0%
Avg return
Earnings day
-7.9%
Avg return
5 days after
-3.2%
Avg return
30 days after
37%
16 / 43 earnings
Positive
+26.5%
Q3 2022
Best reaction
-37.7%
Q4 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +0.0% | -90.0% | — | |
| Q3 2025 | +0.0% | -90.0% | — | |
| Q2 2025 | +1.3% | -9.1% | -27.3% | |
| Q1 2025 | +4.7% | +0.7% | -7.9% | |
| Q4 2024 | -37.7% | -44.3% | -47.0% | |
| Q3 2024 | -25.5% | +12.5% | -1.9% | |
| Q2 2024 | +5.8% | +8.8% | +8.8% | |
| Q1 2024 | +4.3% | -4.3% | -12.2% | |
| Q4 2023 | +19.2% | +5.5% | -6.2% | |
| Q3 2023 | -8.2% | -20.6% | -8.6% | |
| Q2 2023 | -5.2% | -8.7% | -14.5% | |
| Q1 2023 | +2.2% | -1.5% | -27.4% | |
| Q4 2022 | -29.0% | -36.4% | -40.3% | |
| Q3 2022 | +26.5% | +51.2% | +6.0% | |
| Q2 2022 | +20.6% | +14.4% | +4.1% | |
| Q1 2022 | -8.8% | -17.5% | -0.6% | |
| Q4 2021 | -4.9% | +19.8% | +7.7% | |
| Q3 2021 | +0.0% | +0.7% | -34.6% | |
| Q2 2021 | +2.3% | +14.3% | +79.1% | |
| Q1 2021 | -6.6% | -6.7% | -7.4% | |
| Q4 2020 | -7.5% | -9.3% | -14.4% | |
| Q3 2020 | -1.7% | -7.9% | -15.7% | |
| Q2 2020 | -8.5% | -6.8% | -8.9% | |
| Q1 2020 | +2.4% | +13.9% | +118.9% | |
| Q4 2019 | +3.1% | -0.3% | -18.8% | |
| Q3 2019 | -18.2% | -25.6% | +1.8% | |
| Q2 2019 | -23.7% | -36.0% | -51.1% | |
| Q1 2019 | -6.9% | -9.1% | -18.1% | |
| Q4 2018 | -9.7% | -12.1% | -11.5% | |
| Q3 2018 | -6.7% | -13.3% | -19.4% | |
| Q2 2018 | -8.7% | -8.3% | +19.0% | |
| Q1 2018 | +2.6% | -0.5% | -1.2% | |
| Q4 2017 | +20.1% | +12.5% | +35.2% | |
| Q3 2017 | +8.8% | +8.8% | +7.9% | |
| Q2 2017 | +1.7% | +2.4% | +23.2% | |
| Q1 2017 | -3.0% | +4.1% | +0.6% | |
| Q3 2016 | +2.9% | +0.0% | -14.6% | |
| Q2 2016 | -7.2% | -12.6% | -16.9% | |
| Q1 2016 | -5.1% | — | — | |
| Q3 2015 | -10.5% | — | — | |
| Q4 2015 | -10.5% | — | — | |
| Q1 2015 | -0.8% | — | — | |
| Q2 2015 | -0.8% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro